EA
BPMC

Ellsworth Advisors’s Blueprint Medicines BPMC Stock Holding History

Ellsworth Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,173
Closed -$558K – 180
2024
Q2 		$558K Buy
5,173
+330
+7% +$33K 0.16% 124
2024
Q1 		$423K Buy
+4,843
New +$415K 0.12% 144

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ellsworth Advisors's BPMC Position: Q3 2024 in Review

Ellsworth Advisors sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 5,173 shares — an estimated $558K sold.

Ellsworth Advisors first reported a position in BPMC in Q1 2024 and held it in 2 quarters. The position peaked at $558K in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Ellsworth Advisors reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Ellsworth Advisors sold 5,173 Blueprint Medicines shares in Q3 2024, an estimated $558K.
  • Ellsworth Advisors first reported a position in Blueprint Medicines in Q1 2024 and held it in 2 quarters.
  • Ellsworth Advisors's Blueprint Medicines position peaked at $558K in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Ellsworth Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.